Published in Oncotarget on March 07, 2011
Role of maspin in cancer. Clin Transl Med (2013) 1.14
Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget (2012) 1.02
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res (2011) 0.98
Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep (2013) 0.94
BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. Br J Cancer (2014) 0.87
Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells. Mol Cancer (2015) 0.84
Senescent fibroblasts enhance early skin carcinogenic events via a paracrine MMP-PAR-1 axis. PLoS One (2013) 0.84
Protease-activated receptors (PARs)-biology and role in cancer invasion and metastasis. Cancer Metastasis Rev (2015) 0.80
Identification of FLOT2 as a novel target for microRNA-34a in melanoma. J Cancer Res Clin Oncol (2014) 0.79
Expression of MMP-1/PAR-1 and patterns of invasion in oral squamous cell carcinoma as potential prognostic markers. Onco Targets Ther (2015) 0.78
PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo. Oncogene (2015) 0.76
Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. Oncotarget (2016) 0.75
Metastasis regulation by PPARD expression in cancer cells. JCI Insight (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell (1991) 11.51
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science (1994) 5.37
The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem (2001) 4.81
Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost (2005) 4.64
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell (2005) 3.92
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med (1998) 2.42
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther (2006) 2.21
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest (1990) 2.14
Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A (1992) 2.07
Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol (2006) 2.04
Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A (1995) 1.98
Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost (2006) 1.88
Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin (2000) 1.79
The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res (2002) 1.71
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem (2000) 1.64
Connexin 43 enhances the adhesivity and mediates the invasion of malignant glioma cells. J Neurosci (2002) 1.62
Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J (1998) 1.56
Biological functions of maspin. J Cell Physiol (2006) 1.54
Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol (2008) 1.49
Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci (2007) 1.47
Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin Cancer Res (2001) 1.46
Cellular consequences of thrombin-receptor activation. Biochem J (1996) 1.45
Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci (2000) 1.44
Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood (1998) 1.42
The binding of thrombin by fibrin. J Biol Chem (1979) 1.41
Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem (2006) 1.41
The role of altered cell-cell communication in melanoma progression. J Mol Histol (2004) 1.34
Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem (1998) 1.33
Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene (2003) 1.30
Connexin-43 upregulation in micrometastases and tumor vasculature and its role in tumor cell attachment to pulmonary endothelium. BMC Med (2008) 1.29
Protease activated receptors: theme and variations. Oncogene (2001) 1.28
Connexin 43 mediated gap junctional communication enhances breast tumor cell diapedesis in culture. Breast Cancer Res (2005) 1.27
Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res (1995) 1.22
Role of thrombin receptor in breast cancer invasiveness. Br J Cancer (1999) 1.22
Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol (2003) 1.21
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res (2000) 1.21
Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem (2003) 1.19
Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions. Oncogene (2003) 1.17
Connexins and gap junctions in mammary gland development and breast cancer progression. J Membr Biol (2007) 1.15
Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem (2009) 1.14
Adhesive properties of connexin hemichannels. Glia (2008) 1.14
Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clin Cancer Res (2002) 1.13
Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin Biochem (2001) 1.11
Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets (2008) 1.11
Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol (2005) 1.10
Thrombin receptor expression is upregulated in prostate cancer. Prostate (2006) 1.06
Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene (2001) 1.05
A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology (2002) 1.05
Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci U S A (1998) 1.04
Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol (2005) 1.03
Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol (2006) 1.02
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proc Natl Acad Sci U S A (2010) 1.02
Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem (2002) 1.02
Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer (2001) 1.02
Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res (2009) 1.02
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol (2008) 1.02
Advances in the development of siRNA-based therapeutics for cancer. IDrugs (2008) 1.01
Therapeutic potential of retroviral RNAi vectors. Expert Opin Biol Ther (2004) 1.00
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer (2000) 0.98
Adhesion-mediated gap junctional communication between lung-metastatatic cancer cells and endothelium. Invasion Metastasis (1995) 0.98
Cytoplasmic dye transfer between metastatic tumor cells and vascular endothelium. J Cell Biol (1991) 0.98
Strategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem (2008) 0.97
Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med (2002) 0.96
Expression and regulation of tumor suppressor gene maspin in human bladder cancer. Cancer Lett (2004) 0.92
PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism. Oncol Res (2004) 0.92
The promise and challenge toward the clinical application of maspin in cancer. Front Biosci (2004) 0.92
Loss of maspin expression contributes to a more invasive potential in malignant melanoma. Pigment Cell Res (2007) 0.91
Interferons in melanoma. Curr Opin Oncol (1996) 0.88
Protease-activated receptors. Curr Top Dev Biol (2003) 0.84
Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology (2004) 0.83
Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components. J Cutan Med Surg (1999) 0.82
Cloning and identification of regulatory sequences of the human thrombin receptor gene. J Biol Chem (1996) 0.81
Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug resistance. Tumori (2001) 0.78
Maspin and Mutant p53 expression in malignant melanoma and carcinoma: use of tissue microarray. Appl Immunohistochem Mol Morphol (2008) 0.77
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res (2009) 3.07
Focus on bladder cancer. Cancer Cell (2004) 2.59
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther (2003) 2.08
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol (2002) 1.96
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol (2004) 1.84
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res (2007) 1.62
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem (2010) 1.58
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia (2010) 1.51
Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res (2003) 1.49
Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem (2005) 1.38
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res (2004) 1.33
Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem (2009) 1.32
Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res (2006) 1.30
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res (2008) 1.30
Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res (2002) 1.30
Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene (2003) 1.30
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res (2002) 1.27
Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem (2004) 1.24
Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res (2003) 1.23
Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol (2010) 1.23
Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res (2004) 1.22
Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res (2005) 1.22
Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther (2002) 1.21
Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem (2003) 1.19
Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J Biol Chem (2009) 1.18
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res (2006) 1.17
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res (2003) 1.17
Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol (2008) 1.17
The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res (2005) 1.16
Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis (2003) 1.15
EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther (2008) 1.13
The dicey role of Dicer: implications for RNAi therapy. Cancer Res (2010) 1.13
Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res (2005) 1.12
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res (2007) 1.11
MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest (2013) 1.11
Inflammation and melanoma metastasis. Pigment Cell Melanoma Res (2009) 1.11
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res (2005) 1.11
Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1. J Biol Chem (2005) 1.10
Inflammation and melanoma growth and metastasis: the role of platelet-activating factor (PAF) and its receptor. Cancer Metastasis Rev (2007) 1.08
Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther (2008) 1.08
Chitosan hydrogel for localized gene silencing. Cancer Biol Ther (2011) 1.07
A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res (2003) 1.03
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther (2004) 1.03
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res (2009) 1.03
A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res (2008) 1.03
Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol (2006) 1.02
Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proc Natl Acad Sci U S A (2010) 1.02
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia (2008) 1.02
Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res (2009) 1.02
Tumor immunotherapy in melanoma: strategies for overcoming mechanisms of resistance and escape. Am J Clin Dermatol (2008) 1.02
Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res (2006) 1.00
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol (2007) 0.99
Retracted Targeting EGFR in bladder cancer. World J Urol (2007) 0.99
ACTIBIND, an actin-binding fungal T2-RNase with antiangiogenic and anticarcinogenic characteristics. Cancer (2006) 0.98
Expression of Id-1 is regulated by MCAM/MUC18: a missing link in melanoma progression. Cancer Res (2011) 0.98
Forerunner genes contiguous to RB1 contribute to the development of in situ neoplasia. Proc Natl Acad Sci U S A (2007) 0.98
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis. Cancer Res (2011) 0.98
Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy. Lab Invest (2008) 0.96
ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Res (2007) 0.94
BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. Blood (2008) 0.94
Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res (2004) 0.94
Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev (2012) 0.92
CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One (2010) 0.92
Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Microenviron (2008) 0.92
Regulation of gene expression in melanoma: new approaches for treatment. J Cell Biochem (2005) 0.92
Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol (2004) 0.91
Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer (2004) 0.90
Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res (2012) 0.90
Progression elevated gene-3 (PEG-3) induces pleiotropic effects on tumor progression: modulation of genomic stability and invasion. J Cell Physiol (2005) 0.89
Why is melanoma so metastatic? Pigment Cell Melanoma Res (2013) 0.89
ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest (2013) 0.88
The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res (2012) 0.86
ATF-1 mediates protease-activated receptor-1 but not receptor tyrosine kinase-induced DNA synthesis in vascular smooth muscle cells. J Biol Chem (2002) 0.86
Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol (2010) 0.85
Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol (2012) 0.85
A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res (2011) 0.82
The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis. Int J Cancer (2014) 0.82
Monocyte subpopulations in angiogenesis. Cancer Res (2014) 0.81
Gene expression profiling of human cutaneous melanoma: are we there yet? Cancer Biol Ther (2004) 0.78
Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery. Bioconjug Chem (2014) 0.77
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol (2008) 0.77
The HOG-GLI face of melanoma. Pigment Cell Res (2007) 0.77
Construction and expression of intracellular anti-ATF-1 single chain Fv fragment: a modality to inhibit melanoma tumor growth and metastasis. Methods (2004) 0.76